Article Text

other Versions

PDF
Randomised controlled trial
Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection
  1. Mark Danta
  1. Department of Medicine, UNSW, Sydney, Australia
  1. Correspondence to Mark Danta
    Department of Medicine, UNSW, Level 5 deLacy Building, Darlinghurst, Sydney, NSW 2016, Australia; m.danta{at}unsw.edu.au

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMedWeb of Science

Context

Until recently, the standard of care for hepatitis C virus (HCV) infection has been pegylated interferon and ribavirin for 48 weeks for genotype 1 and 24 weeks for genotype 3 infection, with overall sustained virological response (SVR), which equates to cure, of 50% and 80%, respectively. With the recent licensing of the protease inhibitors telaprevir and boceprevir, first generation direct acting antivirals (DAAs), we are at the dawn of a new era of HCV therapy. The ILLUMINATE study explores response-guided therapy in HCV treatment naïve individuals using telaprevir in combination with pegylated interferon and ribavirin.

Methods

ILLUMINATE is a phase 3 non-inferiority study exploring shorter course therapy for HCV infection …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.